Neoadjuvant tyrosine kinase inhibitors in rectal gastrointestinal stromal tumours: a provision for enhanced oncological and functional outcomes

Zachary Zihui Yong1 · Jolene Si Min Wong1 · Melissa Ching Ching Teo1,2 · Claramee Shulyn Chia1,2 · Chin-Ann Johnny Ong1,2,3,4 · Mohamad Farid5 · Grace Hwei Ching Tan1,2

Received: 29 July 2020 / Accepted: 1 January 2021 / Published online: 2 February 2021
© The Author(s) 2021

Abstract
Background  The role of tyrosine kinase inhibitors (TKI) in the neoadjuvant setting and the optimal duration of therapy remains poorly defined. As such, we aim to evaluate the impact of neoadjuvant TKI on oncological and functional outcomes in our cohort of patients with rectal GISTs.

Methods  A retrospective analysis of 36 consecutive patients who underwent treatment for rectal GIST at the National Cancer Centre Singapore from February 1996 to October 2017 was analysed. Surgical, recurrence and survival outcomes between the groups who underwent neoadjuvant therapy and those who underwent upfront surgery were compared.

Results  Patients who received neoadjuvant treatment had significantly larger tumours (median size 7.1 vs. 6.0 cm, \( p = 0.04 \)) and lower mitotic count (> 10 per 50 HPF, 14 vs. 70%, \( p = 0.03 \)) when compared with the non-neoadjuvant group. With TKI pre-treatment (median duration 8.8 months), majority of patients (82%) achieved at least partial response to the therapy coupled with a significant downsizing effect of up to 39% (median size of 7.1–3.6 cm), resulting in similar rates of sphincter-sparing surgery (75 vs. 76%, \( p = 0.94 \)) when compared with the non-neoadjuvant group. In general, neoadjuvant group had lower rates of local recurrence (0 vs. 69%, \( p = 0.04 \)) and higher overall survival (7.4 vs. 5.7 years, \( p = 0.03 \)) as compared to the non-neoadjuvant group.

Conclusions  Neoadjuvant TKI has the benefit of downsizing unresectable rectal GIST to benefit from sphincter-sparing procedure and also confers protection against local recurrence and improves overall survival.

Keywords  Gastrointestinal stromal tumours · Tyrosine kinase inhibitors · Neoadjuvant treatment

Introduction

Gastrointestinal stromal tumours (GISTs) belong to a spectrum of mesenchymal tumours that range from indolent tumours to malignant sarcomas. After acquiring a mutation in the tyrosine kinase receptor c-KIT (CD117), the interstitial cells of Cajal (ICC), which are located in the myenteric plexus in the gastrointestinal wall and serve as a pacemaker of the gut, lose normal growth control and result in tumour formation [1]. The most common site of GISTs is the stomach, while rectal GISTs are rare and occur in only 5% of patients.

Approximately half of the patients at first presentation are not eligible for curative surgical resection due to the presence of metastatic disease [2]. Even with R0 resection, one-third of the patients develop local recurrence illustrating the need for systemic therapy to manage this disease.
apy were collated. Patients recommended for neoadjuvant
TKI prior to surgery improves the outcomes with rectal GIST in our local population and determine if
meeting [9].

reviewed and discussed at a multidisciplinary tumour board
risk classification, imaging and endoscopic findings were
tumour size, mitotic count, stage according to NIH-Fletcher
metastatic disease were excluded from the analysis. Primary
Emission Tomography (PET)-CT scan. Patients with distal
underwent preoperative imaging with a Computed Tomogra-
phy (CT) scan of the chest, abdomen and pelvis or a Positron

Patients' age, gender, race and ECOG status were analyzed.
Preoperative parameters such as
tumour (R) classification and surgical complications were
tabulated. Duration and response to adjuvant imatinib,
together with the DFS and OS, were also compared between
the neoadjuvant and non-neoadjuvant group. DFS is defined
as all GISTs cancer events including local, regional and dis-
tant relapse; second malignancies and deaths without recur-
rence were censored. OS is defined as all deaths including
those without recurrence.

Categorical variables were analyzed using the chi-square
test or Fisher's exact test when cell sizes are small (< 5).
Haldane's approximation was utilized by adding a constant
of 0.5 to each cell if any observed frequencies were 0. The
two-sample t test was used for normally distributed continu-
ous variables while the Mann–Whitney U test was used for
non-parametric continuous variable. p < 0.05 was considered
statistically significant. Statistical analysis was performed on
SPSS version 19.0.

Results
There were 11 patients in the neoadjuvant group and 25 in
the non-neoadjuvant group. The demographics between the
two groups are generally comparable (Table 1). At presen-
tation, patients who received neoadjuvant therapy had sig-
ificantly larger tumour (median size > 10 cm, 33 vs. 0%,
\( p = 0.04 \)) and lower mitotic count (> 10 per 50 HPF, 14 vs.
70%, \( p = 0.03 \)) as compared to patients who did not receive
neoadjuvant therapy.

Neoadjuvant imatinib use

The top reasons for neoadjuvant therapy were due to an
unresectable tumour (55%) or high morbidity surgery
(36%) (Table 2). Most patients received 8.8 months (median
months 4.5–33.9) of neoadjuvant imatinib at 400 mg or
Based on RECIST, majority of patients had at least a partial response to neoadjuvant therapy (82%) resulting in median size reduction of 2.7 cm or 39% size reduction.

Surgical Outcomes after Neoadjuvant Gleevec.

Between the neoadjuvant and non-neoadjuvant groups, both groups underwent similar rates of resection (73 vs. 88%, p = 0.26) and stoma creation (45 vs. 40%, p = 0.76), that was sphincter preserving (75% vs. 76%, p = 0.94), via a minimally surgical approach (26 vs. 34%, p = 0.55) (Table 3). Although it did not reach statistical significance, the neoadjuvant group achieved greater R0 resection (71.4 vs. 56%, p = 0.47) and had fewer surgical complications (9 vs. 16%, p = 0.58). Importantly, the non-neoadjuvant group experienced intraoperative complications (16%) consisting of ruptured or perforated tumour resulting in local and distal recurrence (50% of which were peritoneal recurrence) while the neoadjuvant group had no intraoperative complications and only developed one case of rectosigmoid fistula that was managed with a transanal excision. All patients in the non-neoadjuvant group who did not undergo surgery only had biopsies to confirm the diagnosis and subsequently defaulted follow-up. In terms of CKIT exon 9 mutation, the neoadjuvant group was able to achieve better rates of R0 resection (100 vs. 50%), with lower rates of overall recurrence (100 vs. 50%) as compared to the non-neoadjuvant group. There was no difference in terms of the use of sphincter-sparing approach (100 vs. 100%), surgical complications (0 vs. 0%) and 1-year overall survival (100 vs. 100%) between both groups. Keeping in mind the inherent limitation of running subgroup analysis in such a small population (2 in the non-neoadjuvant group and 1 in the neoadjuvant group), pooled data from various institutions of this rare tumour may better facilitate subgroup analysis to find out if the type of mutation affects the prognosis in the setting of neoadjuvant therapy.

Adjunct Therapy Post-resection.

Although both the neoadjuvant and non-neoadjuvant therapy groups underwent adjuvant therapy (60 vs. 40%, p = 0.28), the neoadjuvant group underwent a shorter duration of adjuvant therapy (2.1 vs. 3.0 years, p = 0.41) and achieved greater rates of complete response (83 vs. 30%, p = 0.22) based on RECIST, though it did not achieve statistical significance (Table 3). In addition, the total duration of imatinib (accounting for both neoadjuvant and adjuvant)

### Table 1 Demographics of non-neoadjuvant and neoadjuvant group

| Results                          | Non-neoadjuvant group (n=25) | Neoadjuvant group (n=11) | p value |
|----------------------------------|------------------------------|--------------------------|---------|
| Age (Median year)                | 58 (37 to 87)                | 60 (32 to 76)            | 0.87    |
| Female                           | 40% (10/25)                  | 46% (5/11)               | 0.76    |
| Race                             |                              |                          | 0.76    |
| Chinese                          | 84% (21/25)                  | 91% (10/11)              |         |
| Malay                            | 12% (3/25)                   | 9% (1/11)                |         |
| Indian                           | 4% (1/25)                    | 0% (0/11)                |         |
| ECOG                             |                              |                          | 0.18    |
| 0                                | 71% (5/7)                    | 100% (7/7)               |         |
| 1                                | 29% (2/7)                    | 0% (0/7)                 |         |
| ≥ 2                              | 0% (0/7)                     | 0% (0/7)                 |         |
| CKIT mutation                    |                              |                          | 0.60    |
| Wild type                        | 7% (1/14)                    | 0% (0/11)                |         |
| Exon 9                           | 14% (2/14)                   | 9% (1/11)                |         |
| Exon 11                          | 79% (11/14)                  | 91% (10/11)              |         |
| Size (Median cm)                 | 6.0 (1.2 to 10.0)            | 7.1 (2.6 to 11.5)        | 0.04*   |
| ≤ 2                              | 19% (3/19)                   | 0% (0/9)                 |         |
| > 2–< 5                          | 26% (5/19)                   | 22% (2/9)                |         |
| > 5–<10                          | 58% (11/19)                  | 44% (4/9)                |         |
| > 10                             | 0% (0/19)                    | 33% (3/9)                |         |
| Mitotic counts                   |                              |                          | 0.03*   |
| 0–5 per 50 HPF                   | 20% (4/20)                   | 71% (5/7)                |         |
| 6–10 per 50 HPF                  | 10% (2/20)                   | 14% (1/7)                |         |
| > 10 per 50 HPF                  | 70% (14/20)                  | 14% (1/7)                |         |
| NIH-Fletcher risk classification  |                              |                          | 0.47    |
| Very low/low                     | 11% (2/19)                   | 25% (2/8)                |         |
| Intermediate                     | 19% (3/19)                   | 25% (2/8)                |         |
| High                             | 74% (14/19)                  | 50% (4/8)                |         |

ECOG Eastern Cooperative Oncology Group

### Table 2 Descriptive analysis of neoadjuvant group

| Results                          | Neoadjuvant group (n=11) | p value |
|----------------------------------|--------------------------|---------|
| Reason for initiation            |                          |         |
| Unresectable                     | 55% (6/11)               |         |
| High morbidity surgery           | 36% (4/11)               |         |
| Does of imatinib                 |                          |         |
| 400 mg                           | 73% (8/11)               |         |
| 300 mg                           | 27% (3/11)               |         |
| Duration (Median months)         | 8.8 (4.5 to 33.9)        |         |
| Response to imatinib             |                          |         |
| Complete response                | 9% (1/11)                |         |
| Partial response                 | 82% (9/11)               |         |
| No response                      | 9% (1/11)                |         |
| Progressive disease              | 0% (0/11)                |         |
| Post-neoadjuvant size (Median cm)| 3.6 (2.6 to 11.0)        |         |
| Size reduction (Median cm, %)    | 2.7, 39% (0–6.1, 0–61%)  |         |

300 mg (73 vs. 27%). Based on RECIST, majority of patients had at least a partial response to neoadjuvant therapy (82%) resulting in median size reduction of 2.7 cm or 39% size reduction.
were comparable between both groups (2.0 vs. 3.1 median years, \( p = 0.40 \)).

**Recurrence and survival outcomes**

The recurrence rate for the neoadjuvant group was statistically lower than the non-neoadjuvant group (18 vs. 64%, \( p = 0.01 \), with the former having a lower rate of local recurrence (0 vs. 69%, \( p = 0.04 \)) (Table 4). There were no cases of local recurrence in the neoadjuvant group while the median time to local recurrence in the non-neoadjuvant group was 3.9 years. On the other hand, the median time to distant recurrence in the neoadjuvant and non-neoadjuvant groups were comparable (3.3 vs. 3.6 years, \( p = 0.63 \)). For both groups, all recurrence cases did not undergo surgical treatment. Instead, adjuvant chemotherapy was restarted in 75% (12/16) and 100% (2/2) in the neoadjuvant group. Unfortunately, 7 patients are still currently undergoing therapy and we are unable to run further analysis to evaluate the efficacy of the treatment. There were 2 neoadjuvant cases that experienced tumour recurrence, specifically distal recurrence involving the liver and peritoneum. Both cases had C-kit exon 11 mutation and experienced recurrence at 3.4 and 3.3 year after the initial surgery, respectively. Both cases are still undergoing imatinib therapy. The neoadjuvant group had a longer OS (7.4 vs. 5.7 years, \( p = 0.03 \)) as compared to the non-neoadjuvant group (Fig. 1). Although it did not achieve statistically significance, the early 1-year DFS (100 vs. 94%, \( p = 0.72 \)) and OS (100 vs. 100%) and 3-year DFS (100 vs. 75%, \( p = 0.42 \)) and OS (91 vs. 84%, \( p = 0.59 \)) between the neoadjuvant and non-neoadjuvant groups were similarly high. At the 5-year mark, the neoadjuvant group had poorer DFS (0 vs. 31%, \( p = 0.35 \), but had better OS (82 vs. 68%, \( p = 0.39 \)) as compared to the non-neoadjuvant group.

---

**Table 3** Outcome of non-neoadjuvant and neoadjuvant group

| Results                              | Non-neoadjuvant group | Neoadjuvant group | \( p \) value |
|--------------------------------------|-----------------------|-------------------|---------------|
|                                      | (\( n = 25 \))        | (\( n = 11 \))    |               |
| Surgical resection                   | 88% (22/25)           | 73% (8/11)        | 0.26          |
| Surgical approach                    |                       |                   | 0.55          |
| Transanal                            | 29% (6/21)            | 13% (1/8)         |               |
| Laparoscopic                         | 5% (1/21)             | 13% (1/8)         |               |
| Open                                 | 67% (14/21)           | 75% (6/8)         |               |
| Extend of surgery                    |                       |                   |               |
| Sphincter sparing                    | 76% (16/21)           | 75% (6/8)         | 0.94          |
| Stoma creation                       | 40% (10/25)           | 45% (5/11)        | 0.76          |
| Extend of resection                  |                       |                   | 0.47          |
| R0                                   | 56% (10/18)           | 71.4% (5/7)       | (5/7)         |
| R1                                   | 44% (8/18)            | 29% (2/7)         | (2/7)         |
| Surgical complications               | 16% (4/25)            | 9% (1/11)         | 0.58          |
| Ruptured tumour                      | 50% (2/4)             | 0% (0/1)          |               |
| Perforated tumour                    | 50% (2/4)             | 0% (0/1)          |               |
| Fistula                              | 0% (0/4)              | 100% (1/1)        |               |
| Adjuvant therapy                     | 40% (10/25)           | 60% (6/10)        | 0.28          |
| Dose of adjuvant imatinib            |                       |                   | 0.23          |
| 400 mg                               | 100% (8/8)            | 83% (5/6)         |               |
| 300 mg                               | 0% (0/8)              | 17% (1/6)         |               |
| Duration of imatinib (Median year)   | 3.0 (0.3 to 6.2)      | 2.1 (0.3 to 2.5)  | 0.41          |
| Total duration of imatinib (Median year) | 3.1 (0.3 to 6.2)     | 2.0 (0.3 to 3.1)  | 0.40          |
| Response to imatinib                 |                       |                   | 0.22          |
| Complete response                    | 30% (3/10)            | 83% (5/6)         | (5/6)         |
| Partial response                     | 10% (1/10)            | 0% (0/6)          | (0/6)         |
| No response                          | 10% (1/10)            | 0% (0/6)          | (0/6)         |
| Progressive disease                  | 50% (5/10)            | 17% (1/6)         |               |
Discussion

The applicability of imatinib for the treatment of GIST in the neoadjuvant setting is an area of huge research interest. The National Comprehensive Cancer Network recommends neoadjuvant systemic therapy for borderline-resectable or oligometastatic metastatic GIST on a case-to-case basis [11]. It recommends that preoperative imatinib treatment should be considered if abdominoperineal resection or multivisceral resection is necessary to achieve a negative resection margin. On the other hand, the European Society for Medical Oncology guidelines recommend neoadjuvant therapy if R0 resection is feasible, achieved by less mutilating surgery, safer surgical procedure, lesser blood loss and lower risk of tumour rupture [12].

However, the inclusion criteria and optimal duration for neoadjuvant therapy remain poorly defined. Some studies have recommended a tumour size cut-off of 5 cm to initiate preoperative imatinib therapy while other studies have recommended initiation in high-risk tumours [3, 8, 13–16]. RTOG 0132/ACRIN 6665 study recommended duration of 8–12 weeks of preoperative therapy while other smaller studies saw benefit for treatment duration of 6–15 months [3, 14, 15, 17–20]. Besides having no definitive information on the length of neoadjuvant therapy, there is also a paucity of data on the ideal clinical endpoint. Based on the limited data that were published, a final tumour size of 1.8–6.9 cm after 19–63% reduction conferred surgical and/or survival benefit [14, 16, 20–26].

Our study’s findings may provide further insights insofar as to aid the future development of a neoadjuvant therapy guidelines. We found that patients who received neoadjuvant therapy had larger tumours (7.1 vs. 6.0 cm, \( p = 0.04 \)) compared to those who had no neoadjuvant therapy. A duration of 8.8 months of neoadjuvant therapy was useful in downsizing tumour to a median size of 3.6 cm after a 2.7 cm or 39% size reduction to improve resectability to the extent of achieving R0 resection, with low complications and improvements in sphincter-sparing rates. Neoadjuvant TKI improved the eligibility of sphincter-sparing procedures to the level that was comparable to the non-neoadjuvant group for patients who were considered to be surgically inoperable or challenging. Notably, neoadjuvant therapy generally conferred protection from local recurrence and improved OS regardless of tumour size and tumour risk stratification.

In reported literature, the mean size of GIST ranges from 10 to 13 cm with those greater than 5 cm more likely to be symptomatic (e.g. bleeding and abdominal pain) [1, 27]. On the other hand, due to the paucity of space in the pelvis, rectal GIST tends to become symptomatic at a smaller size and present with a mean size of 4.8 cm [15]. The high mitotic activity in rectal GISTs remains the main determinant factor in their risk categorization (not their size). In addition,

| Results | Non-neoadjuvant group | Neoadjuvant group | \( p \) value |
|---------|-----------------------|-------------------|--------------|
| % (n)   | % (n)                 |                   |              |
| Recurrence | 64% (16/25) | 18% (2/11) | 0.01* |
| Local   | 69% (11/16) | 0% (0/2) | 0.04* |
| Distal  | 63% (10/16) | 100% (2/2) | 0.29 |
| Site of distal metastasis | | | 0.30 |
| Liver   | 50% (5/10) | 50% (1/2) | | |
| Peritoneal | 10% (1/10) | 50% (1/2) | | |
| Multiple | 40% (4/10) | 0% (0/2) | | |
| Time to local recurrence (Median year) | 3.9 (0.9 to 15.1) | - | |
| Time to distal recurrence (Median year) | 3.6 (0.9 to 10.4) | 3.3 (3.3 to 3.4) | 0.63 |
| 1-year disease-free interval | 94% (15/16) | 100% (2/2) | 0.72 |
| 3-year disease-free interval | 75% (12/16) | 100% (2/2) | 0.42 |
| 5-year disease-free interval | 31% (5/16) | 0% (0/2) | 0.35 |
| Overall survival (Median year) | 5.7 (1.5 to 13.5) | 7.4 (1.7 to 20.3) | 0.03* |
| 1-year overall survival | 100% (25/25) | 100% (11/11) | - |
| 3-year overall survival | 84% (21/25) | 91% (10/11) | 0.59 |
| 5-year overall survival | 68% (17/25) | 82% (9/11) | 0.39 |
a predominance of rectal GISTs has KIT exon 11 deletions, which has been linked to adverse outcomes [28]. Interestingly, we found out that the patients who had neoadjuvant therapy had initial lower mitotic count, which suggested that they might be inherently less aggressive as compared to the non-neoadjuvant as evident by lower high-risk tumours by NIH-Fletcher risk classification (50 vs. 74%, $p = 0.47$).

Surgical resection with negative margins represents the most effective chance of long-term survival in patients with non-metastatic, low-risk GISTs [12]. Likewise, the mainstay of treatment for rectal GISTs is complete resection with clear margins without mandatory lymph node dissection (lymphatic metastases are exceedingly rare). There is good clinical outcome in general for resectable tumours but it is accompanied with a high rate of recurrence and metastasis within 2 years [6]. Owing to the rarity of rectal GIST, no standard surgical treatment exists for tumours localized in the rectum. Conventional surgical methods to treat rectal GISTs include abdominoperineal resection, total exentation and anterior resection. A large proportion of rectal GIST is also accessible to local excision via transtinal, transsacral or transvaginal approaches. Local excision has been reported to decrease the risk of peritoneal recurrence as it preserves the integrity of the peritoneum at the rectosigmoid junction. The choice of procedure depends on the location; tumour size, extent and the probability in achieving clear margins. In anatomical challenging cases due to tumour size, location and relationship with pelvic structures, abdominoperineal or multivisceral resections may be performed, but raises the problem of sphincter preservation. Extensive surgery may result in considerable functional morbidity. Therefore, it is important to consider the balance of radical resection with the preservation of the anal, urinary and sexual function in the surgical treatment of rectal GIST. Generally, wide margins are not necessary if a clear resection margin is obtained. Although extended surgery achieves more R0 resection compared with conservative surgery, the rate of tumour recurrence is comparable between both groups as illustrated by the study by Khalifa et al. who reported no difference in survival rates between local excision and abdominoperineal resection for patients with rectal GISTs [29].

Adjuvant imatinib following surgery is well established for high risk GISTs. According to two independent high-impact studies conducted by Joensuu et al. and Mietinen et al., the initiation of adjuvant imatinib for high-risk rectal GIST to decrease the risk of recurrence and metastasis is recommended [30, 31]. In addition, incomplete surgical resection or intraoperative tumour rupture are also common reasons for patients to start adjuvant imatinib postoperatively. Unlike the duration of neoadjuvant therapy, the optimal duration for adjuvant therapy has been defined as 3 years [31]. The need for adjuvant therapy for patients with low-risk GIST who respond to neoadjuvant imatinib and have undergone complete surgical resection remains unanswered.

In this study, we found that neoadjuvant therapy enabled a modification in tumour size and/or density to permit the utility of minimally invasive sphincter-sparing surgery in 36% of our patients. It is important to note that resistance to relevant secondary mutations may occur after neoadjuvant therapy and hence the duration of treatment should be as short as possible to facilitate timely complete resection [32]. Neoadjuvant therapy can be continued until the regression of the tumour size or metabolic activity reaches a plateau phase as the development of secondary KIT mutations is common in protracted treatment duration. As a result, Haller et al. advised to continue therapy until stagnation of tumour shrinkage is obtained, which signifies that maximum effect has been achieved [20]. Given the fact that most of the response to imatinib occurs within 6 months of therapy, surgery should be done promptly at approximately 6 months of therapy before the development or selection of clones.
with secondary mutations. Therefore, mutational analysis is crucial to distinguish the resistant genotypes that will not respond to targeted therapy in order to avoid delay of surgical excision. Mutations in exon 11 of KIT have been generally associated with tumours that are imatinib-sensitive while tumours with mutation in exon 9 tend to be resistant to imatinib [33]. In general, imatinib can be safely discontinued 2–3 days prior to surgery and can restart immediately once patient recovers from the surgery.

Different imaging modalities are used to monitor the response after systemic therapy. The most commonly used is RECIST [10]. However, RECIST has some inherent limitations as it focuses mainly on size reduction. The Choi response criteria are purported to be a better alternative as it is based on both a decrease in tumour size and tumour density on contrast-enhanced CT leading to better prediction of time to tumour progression [34]. In cases with imaging ambiguity, PET can complement CT scans [35]. PET scan allows quantitative comparison of tumour metabolism different time points. GIST responsiveness to imatinib can be seen as early as 1 week after initiation of therapy and more than 25% reduction in metabolism is considered to be an adequate response to systemic therapy. In addition, PET scan is especially useful in the neoadjuvant setting as it may affect clinical decision to proceed with surgical resection or continuing systemic therapy as it can detect early evaluation of neoadjuvant imatinib response better than CT scans [36].

Given the complexity and rarity of rectal GIST, a multidisciplinary approach with a team of surgical oncologists, medical oncologists, radiologists and pathologists with expertise in sarcomas is imperative to provide tailored management for the patient. Recurrence can develop up to 10–15 years after surgical therapy and therefore requires long-term follow-up.

Inferences drawn from our study should be tempered by the fact that it is based on a single-centre retrospective study. The retrospective nature of this study renders it susceptible to selection bias. Given that this is a single centre study looking at a rare condition, it is compounded by the low incidence of rectal GIST resulting in our study sample to be small and hence prone to type 2 errors. Also, there are no optimal cut-off values for initiation and termination for neoadjuvant therapy. Future studies in the area of inflammatory indices may look into optimal cut-offs for patients. In addition, patients selected for neoadjuvant imatinib and the selection of surgical technique were also not properly defined. The lack of these selection criteria muddles the conclusion of our study. Furthermore, in Tables 1 and 3, 10 of 17 patients in the non-neoadjuvant group with intermediate and high-risk tumours received adjuvant therapy, whereas all 6 patients in the neoadjuvant group with intermediate and high-risk tumours received adjuvant therapy. This might lead to bias in the survival difference seen between the two arms.

Although this study is small in number and respective in designs, it adds to the increasing evidence to support the use of neoadjuvant imatinib therapy for the treatment of rectal GIST. In selected cases that are not amenable with surgical resection at the onset, administration of neoadjuvant imatinib of approximately 9 months has the benefit of reducing the tumour size by 39% to improve resectability to achieve R0 resection with low complication rates using sphincter-sparing techniques. In addition, it confers protection from local recurrence and improved OS regardless of tumour size and tumour risk stratification. The benefits of neoadjuvant imatinib also extend to GIST of other sites. Neoadjuvant imatinib has been shown to downsize tumour to achieve complete surgical resection in gastroesophageal GIST [37–41]. The landmark paper from EORTC STBSG sarcoma centres had consensual results for upper gastrointestinal GIST, which noted a median overall survival of 8.6 years in the neoadjuvant group [42].

In conclusion, our study found that a therapeutic strategy that combines neoadjuvant imatinib therapy with surgery should be considered for patients with rectal GISTs that are large, marginally resectable or unresectable or have a close relationship with vital pelvic structures, such as anal sphincters or nerves. Neoadjuvant imatinib may potentially increase the proportion of patients able to undergo curative conservative surgical therapy rather than the more morbid extended resection.

Acknowledgements CAJO is supported by the National Research Council Transition Award (NMRC/TA/0061/2017).

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Valsangkar N, Sehdev A, Misra S, Zimmers TA, O’Neil BH, Koniaris LG (2015) Current management of gastrointestinal stromal tumours: Surgery, current biomarkers, mutations, and therapy. Surgery 158(5):1149–1164. https://doi.org/10.1016/j.surg.2015.06.027

2. Gervaz P, Huber O, Morel P (2009) Surgical management of gastrointestinal stromal tumours. Br J Surg 96(6):567–578. https://doi.org/10.1002/bjs.6601
3. Liu H, Yan Z, Liao G, Yin H (2014) Treatment strategy of rectal gastrointestinal stromal tumor (GIST). J Surg Oncol 109(7):708–713. https://doi.org/10.1002/jso.23562

4. Eisenberg BL, Pipas JM (2012) Gastrointestinal stromal tumor—background, pathology, treatment. Hematol Oncol Clin North Am 26(6):1239–1259. https://doi.org/10.1016/j.hoc.2012.08.003

5. von Mehren M (2016) Management of gastrointestinal stromal tumors. Surg Clin North Am 96(5):1059–1075. https://doi.org/10.1016/j.suc.2016.05.011

6. Yasui M, Tsujinaka T, Mori M, Takahashi T, Nakashima Y, Nishida T, Kinki GSG (2017) Characteristics and prognosis of rectal gastrointestinal stromal tumors: an analysis of registry data. Surg Today 47(10):1188–1194. https://doi.org/10.1007/s11295-017-1524-8

7. Demetri GD, Von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347(7):472–480

8. Wilkinson MJ, Fitzgerald JE, Strauss DC, Hayes AJ, Thomas JM, Messiou C, Fisher C, Benson C, Tekkis PP, Judson I (2015) Surgical treatment of gastrointestinal stromal tumour of the rectum in the era of imatinib. Br J Surg 102(8):965–971. https://doi.org/10.1002/bjs.9818

9. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O’Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33(5):459–465. https://doi.org/10.1016/S0046-8177(02)02135-4

10. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Roman L, Cleary L, Whtern J, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247. https://doi.org/10.1016/j.ejca.2008.10.026

11. von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, Bonvalot S, Bouckovinas I, Bovee J, Brodowicz T, Broto JM, Buonadonna SV, Meyer C, Morris ZS, O’Donnell RJ, Pappo AS, Paz IB, Perrotte P, Petersen IA, Pfeifer JD, Riedel RF, Ruo B, Schuetze S, Tap S, Tielen R, Verhoef C, van Coevorden F, van der Graaf W, Whelan J, Wardelmann E, Zaikova O, Blay JY, Committee EG, Euracan (2018) Gastrointestinal stromal tumors: revised RECIST guideline (version 1.1). Eur J Cancer 81:iv68–iv78. https://doi.org/10.1093/annonc/mdy095

12. Casali PG, Abecassis N, Bauer S, Biagini R, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347(7):472–480

13. Hawkins AT, Wells KO, Krishnamurty DM, Hunt SR, Mutch MG, Glasgow SC, Wise PE, Siliviera ML (2017) Preoperative chemotherapy and survival for large anorectal gastrointestinal stromal tumors: a national analysis of 333 cases. Ann Surg Oncol 24(5):1195–1201. https://doi.org/10.1245/s10434-016-5706-1

14. Tielen R, Verhoef C, van Coevorden F, Reynolds AK, van der Graaf WT, Bonenkamp JJ, van Etten B, de Wit JH (2013) Surgical management of rectal gastrointestinal stromal tumors. J Surg Oncol 107(4):320–323. https://doi.org/10.1002/jso.23223

15. Jakob JMC, Ronellenfitsch U, Wardemann E, Negri T, Gronchi A, Hohenberger P (2013) Gastrointestinal stromal tumor of the rectum—results of surgical and multimodality therapy in the era of imatinib. Ann Surg Oncol 20(2):586–592. https://doi.org/10.1245/s10434-012-2647-1

16. Ueki T, Nagayoshi K, Manabe T, Maeyama R, Yokomizo A, Yamamoto H, Oda Y, Tanaka M (2014) Laparoscopic en bloc excision of gastrointestinal stromal tumors of the rectum after neoadjuvant imatinib therapy: anteriorly extended intersphincteric resection combined with partial resection of the prostate. Tech Coloproctol 19(4):247–251. https://doi.org/10.1007/s10151-014-1261-6

17. Eisenberg BL, Harris J, Blanke CD, Demetri GD, Heinrich MC, Watson JC, Hoffman JP, Okuno S, Kane JM, von Mehren M (2009) Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol 99(1):42–47. https://doi.org/10.1002/jso.21160

18. Huynh TKMP, Cassier P, Bouché O, Lardièere-Deguelle S, Adenis A, André T, Mancini J, Collard O, Montemurro M, Bompas E, Riós M, Isambert N, Cupissol D, Blay JY, Duffaud F (2014) Primary localized rectal/pararectal gastrointestinal stromal tumor—results of surgical and multimodal therapy from the French Sarcoma group. BMC Cancer 14:156

19. Zanwar S, Ostwal V, Sahu A, Jain D, Ramaswamy A, Saklani A, Ramadwar M, Shetty N, Shrikande SV (2016) Rectal GIST—outcomes and viewpoint from a tertiary cancer center. Indian J Gastroenterol 35(6):445–449. https://doi.org/10.1007/s12664-016-0710-8

20. Haller F, Detken S, Schulten HJ, Happel N, Gunawan B, Kuhl gutz J, Fuzesi L (2007) Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations. Ann Surg Oncol 14(2):526–532. https://doi.org/10.1245/s10434-006-9228-0

21. Fujimoto Y, Akiyoshi T,Konishi T, Nagayama S, Fukunaga Y, Ueno M (2014) Laparoscopic sphincter-preserving surgery (intersphincteric resection) after neoadjuvant imatinib treatment for gastrointestinal stromal tumor (GIST) of the rectum. Int J Colorectal Dis 29(1):111–116. https://doi.org/10.1007/s00384-013-1769-7

22. Ebihara Y, Okushiba S, Kawaiwa Y, Kitashiro Y, Hondo K (2008) Neoadjuvant imatinib in a gastrointestinal stromal tumor of the rectum: report of a case. Surg Today 38(2):174–177. https://doi.org/10.1007/s10593-007-9359-5

23. Kaneko M, Nozawa H, Emoto S, Murono K, Sasaki A, Otani K, Nishikawa T, Tanaka T, Kiyomatsu T, Hata K, Kawaiw K, Watanabe T (2017) Neoadjuvant Imatinib therapy followed by intersphincteric resection for low rectal gastrointestinal stromal tumors. Asian Cancer Res 37(9):5155–5160. https://doi.org/10.21873/anticancerres.11936

24. Kyo K, Azuma M, Okamoto K, Nishiyama M, Shimamura T, Yamanaka T, Ishida R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Silverman SG, Silberman SL, Capdeville R, Bienemann A, Ama M, Kanamaru H, Hirakawa M, Nakamura T, Shinmura K, Koda K, Yokoyama H (2016) Neoadjuvant imatinib treatment and laparoscopic anus-preserving surgery for a large gastrointestinal stromal tumor of the rectum. World J Surg Oncol 14:68. https://doi.org/10.1186/s12957-016-0837-1

25. Kramp KH, Omer MG, Schoffski P, d’Hoore A (2015) Sphincter sparing resection of a large obstructive distal rectal gastrointestinal stromal tumor: a national analysis of 333 cases. Ann Surg Oncol 24(5):1195–1201. https://doi.org/10.1245/s10434-016-5706-1
stromal tumour after neoadjuvant therapy with imatinib (Glivec). BMJ Case Rep. https://doi.org/10.1136/bcr-2014-207775

26. Wang J-P, Wang T, Huang M-J, Wang L, Kang L, Wu X-J (2011) The Role of neoadjuvant imatinib mesylate therapy in sphincter-preserving procedures for anorectal gastrointestinal stromal tumor. Am J Clin Oncol 34(3):314–316. https://doi.org/10.1097/COC.0b013e3181dea970

27. Kukar M, Kapil A, Papenfuss W, Groman A, Grobmyer SR, Hochwald SN (2015) Gastrointestinal stromal tumors (GISTs) at uncommon locations: a large population based analysis. J Surg Oncol 111(6):696–701. https://doi.org/10.1002/jso.23873

28. Ricci RMM, Cenci T, Antinori A, Cassano A, Larocca LM (2016) Case of rectal GI stromal tumor demonstrating that KIT and PDG-FRA mutations are not always mutually exclusive. J Clin Oncol 34(12):107–109

29. Khalifa AABW, Rao VK, Williams MJ (1986) Leiomyosarcoma of the rectum. Report of a case and review of the literature. Dis Colon Rectum 29(6):427–432

30. Miettinen MFM, Sarlomo-Rikala M, Burke A, Sobin LH, Lasota J (2001) Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus—a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. Am J Surg Pathol 25(9):1121–1133

31. Joensuu HEM, Sundby Hall K, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Monge OR, Bono P, Kallio R, Vehtari A, Leinonen M, Balázs L, Hahnfeld D, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Monge OR, Bono P, Kallio R, Vehtari A, Leinonen M, Alvegård T, Reichardt P (2012) One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor—a randomized trial. JAMA 307(12):1265–1272

32. Wardelmann E (2006) Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 12(6):1743–1749. https://doi.org/10.1158/1078-0432.CCR-05-1211

33. Vadakara J, von Mehren M (2013) Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies. Hematol Oncol Clin North Am 27(5):905–920. https://doi.org/10.1016/j.hoc.2013.07.007

34. Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Charmsangavej C (2007) We should desist using RECIST, at least in GIST. J Clin Oncol 25(13):1760–1764. https://doi.org/10.1200/JCO.2006.07.3411

35. Van den Abbeele AD (2008) The lessons of GIST–PET and PET/CT: a new paradigm for imaging. Oncologist 13(Suppl 2):8–13. https://doi.org/10.1634/theoncologist.13-S2-8

36. Farag S, Geus-Oei L-F, van der Graaf WT, van Coevorden F, Grunhagen D, Reyners AKL, Boonstra PA, Desai I, Gelderblom H, Steeghs N (2018) Early evaluation of response using 18F-FDG PET influences management in gastrointestinal stromal tumor patients treated with neoadjuvant imatinib. J Nucl Med 59(2):194–196. https://doi.org/10.2967/jnumed.117.196642

37. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay J-Y, Issels R, van Oosterom A, Hogendoorn PCW, Van Glabbeke M, Bertulli R, Judson I (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364(9440):1127–1134. https://doi.org/10.1016/s0140-6736(04)17098-0

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.